2Riccobene T,Jakate A,Rank D. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects ,healthy elderly subjects, and subjects with renal im- pairment or end-stage renal disease requiring hemodialysis I-J]. J Clin Pharmacol, 2014,54(7) : 742-752. 被引量：1
3Camins BC. Prevention and treatment of hemodialysis-related bloodstream infections[J]. Semin Dial, 2013,26(4) : 476-481. 被引量：1
4Tanhehco YC, Berns JS. Red blood cell transfusion risks in patients with end-stage renal disease[J]. Semin Dial, 2012,25 (5) :539-544. 被引量：1
5McGill JB,Yki-Jarvinen H,Crowe S,et al.Combination of the dipeptidyl peptidase-4inhibitor linagliptin with insulinbased regimens in type 2diabetes and chronic kidney disease[J].Diab Vasc Dis Res,2015,12(4):249-257. 被引量：1
6Kilpatrick ES,Bloomgarden ZT.Comment on:Selvin et al.No racial differences in the association of glycated hemoglobin with kidney disease and cardiovascular outcomes.Diabetes care 2013;36:2995-3001[J].Diabetes Care,2013,36(12):e215. 被引量：1
7Schneider AG,Bellomo R,Bagshaw SM,et al.Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury:a systematic review and meta-analysis[J].Intensive Care Med,2013,39(6):987-997. 被引量：1
